These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36781332)

  • 1. mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia.
    Li R; Liu H; Fairley CK; Ong JJ; Guo Y; Lu P; Zou Z; Xie L; Zhuang G; Li Y; Shen M; Zhang L
    Vaccine; 2023 Apr; 41(15):2439-2446. PubMed ID: 36781332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States.
    Li R; Liu H; Fairley CK; Zou Z; Xie L; Li X; Shen M; Li Y; Zhang L
    Int J Infect Dis; 2022 Jun; 119():87-94. PubMed ID: 35338008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact and economic value of booster vaccination with Pfizer-BioNTech COVID-19 vaccine, bivalent (Original and Omicron BA.4/BA.5) in the United States.
    Di Fusco M; Marczell K; Thoburn E; Wiemken TL; Yang J; Yarnoff B
    J Med Econ; 2023; 26(1):509-524. PubMed ID: 36942976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA.
    Li R; Lu P; Fairley CK; Pagán JA; Hu W; Yang Q; Zhuang G; Shen M; Li Y; Zhang L
    Appl Health Econ Health Policy; 2024 Jan; 22(1):85-95. PubMed ID: 37910314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study.
    Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Petrone D; Bressi M; Del Manso M; Siddu A; Proietti V; Battilomo S; Menniti-Ippolito F; Popoli P; Bella A; Riccardo F; Palamara AT; Rezza G; Brusaferro S; Pezzotti P;
    Vaccine; 2023 Jan; 41(1):76-84. PubMed ID: 36400660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China.
    Fu Y; Zhao J; Wei X; Han P; Yang L; Ren T; Zhan S; Li L
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan.
    Nagano M; Kamei K; Matsuda H; Takahashi C; Yang J; Wada K; Yonemoto N
    Expert Rev Vaccines; 2024; 23(1):349-361. PubMed ID: 38411109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Korves C; Izurieta HS; Smith J; Zwain GM; Powell EI; Balajee A; Ryder KM; Young-Xu Y
    Vaccine; 2022 Aug; 40(33):4742-4747. PubMed ID: 35773122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
    Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era.
    Ioannou GN; Bohnert ASB; O'Hare AM; Boyko EJ; Maciejewski ML; Smith VA; Bowling CB; Viglianti E; Iwashyna TJ; Hynes DM; Berry K;
    Ann Intern Med; 2022 Dec; 175(12):1693-1706. PubMed ID: 36215715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
    Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB
    Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of first and second COVID-19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021-July 2022.
    Petrie JG; King JP; McClure DL; Rolfes MA; Meece JK; Pattinson D; Neumann G; Kawaoka Y; Belongia EA; McLean HQ
    Influenza Other Respir Viruses; 2023 Mar; 17(3):e13104. PubMed ID: 36875208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of fractional doses of COVID-19 vaccine boosters in India.
    Du Z; Wang L; Bai Y; Feng S; Ramachandran S; Lim WW; Lau EHY; Malani A; Cowling BJ
    Med; 2023 Mar; 4(3):182-190.e3. PubMed ID: 36827972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.